By Robert Preidt

HealthDay Reporter

SATURDAY, Nov. 10, 2018 (HealthDay News) — The diabetes drug Farxiga may do double-duty for sufferers, serving to to push back some other killer, center failure, new analysis displays.

Type 2 diabetics who took Farxiga (dapagliflozin) noticed their odds of hospitalization for center failure drop by means of 27 p.c in comparison to those that took a placebo, in step with a find out about funded by means of the drug’s maker, Astra-Zeneca.

“When it involves serving to our sufferers regulate and set up blood glucose, the ‘how’ seems to be as vital [as] the ‘how a lot,” stated find out about creator Dr. Stephen Wiviott, a cardiovascular drugs specialist at Brigham and Women’s Hospital in Boston.

“When opting for a remedy, trial effects like those can assist us make an educated determination about what therapies aren’t best protected and efficient for decreasing blood glucose however too can scale back chance of center and kidney headaches,” Wiviott stated in a health center information liberate.

The findings had been printed Nov. 10 within the New England Journal of Medicine, to coincide with their presentation at the yearly assembly of the American Heart Association in Chicago.

The new find out about incorporated greater than 17,000 sort 2 diabetes sufferers elderly 40 and older. Nearly 7,000 had center illness and greater than 10,000 had a large number of chance components for center illness, Wiviott’s team stated.

Patients had been randomly assigned to take both a “dummy” placebo tablet or 10 milligrams of Farxiga on a daily basis.

Taking the drug didn’t scale back the chance of center assault, stroke and cardiovascular-related loss of life, the analysis crew discovered. However, sufferers who took the drug did see wholesome declines of their blood sugar ranges, plus an added bonus: a 27 p.c lower of their chance of hospitalization for center failure.

Their chance of kidney failure and loss of life from kidney failure additionally fell, the Boston crew stated.

Farxiga is a kind of drug referred to as a SGLT2 inhibitor. Two different contemporary research of this elegance of substances display that they “robustly and consistently improve heart and [kidney] outcomes in a broad population of patients with diabetes,” Wiviott famous.


One heart specialist who wasn’t concerned within the find out about stated the findings are welcome information for other folks with diabetes.

“Sadly, more than 70 percent of deaths in diabetic patients is from cardiovascular causes,” stated Dr. Cindy Grines, who heads cardiology at North Shore University Hospital, in Manhasset, N.Y.

She famous that, prior to now, there was once fear that some diabetes drugs may hurt the guts, however this new find out about displays that “there are now newer drugs available that have beneficial cardiovascular effects.”

Grines famous that fluid buildup is a trademark of center failure. And as a result of Farxiga “works by increasing the excretion of glucose in urine, it is not surprising that it reduces heart failure.”

However, she discovered it sudden that the drug did not decrease charges of center assault or stroke.

The commonplace diabetes drug metformin has been proven to decrease the chance for those cardiac occasions, alternatively. So, “I would chose [Farxiga] to add to metformin in patients with congestive heart failure,” Grines added.

According to Grines, sufferers with center problems will have to keep away from one elegance of diabetes medicine particularly.

“Multiple studies have shown that sulfonylurea drugs — glipizide, glyburide and glimepiride — increasedcardiovascular mortality, heart attack and congestive heart failure” she stated, “so sulfonylureas should be avoided in all cardiac patients.”

Another center specialist agreed that more recent drugs akin to Farxiga are making improvements to remedy for other folks with sort 2 diabetes.

Farxiga is “a welcomed addition to our armamentarium to reduce heart failure,” stated Dr. Marcin Kowalski, a heart specialist at Staten Island University Hospital in New York City. “It is also uplifting that this group of medications did not increase [negative] cardiovascular outcomes.”

WebMD News from HealthDay


SOURCES: Cindy Grines, M.D.,chair, cardiology,North Shore University Hospital, Manhasset, N.Y., and Long Island JewishMedical Center, New Hyde Park, N.Y.; MarcinKowalski,M.D.,heart specialist, Staten Island University Hospital, New York City; Brigham and Women’s Hospital, information liberate, Nov. 10, 2018

Copyright © 2013-2018 HealthDay. All rights reserved.